Effect of selegiline on mortality in patients with Parkinson's disease: A meta analysis

Neurology

Volumn 51, Issue 3, 1998, Pages 825-830

  Olanow, C Warren ^a   Myllyla V V ^b   Sotaniemi, K A ^b   Larsen, J P ^c   Palhagen S ^d   Przuntek, H ^e   Heinonen, E H ^f   Kilkku, O ^f   Lammintausta, R ^f   Maki Ikola O ^f   Rinne, U K ^g  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OULU   (Finland)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d RYHOV COUNTY HOSPITAL   (Sweden)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f ORION CORPORATION   (Finland)

^g UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0031750983     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.3.825     Document Type: Article

References (40)

1. Birkmayer W, Riederer P, Youdim MBH, Linauer W. The potentiation of the antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36:303-326.
2. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11:45-55.
3. Heinonen EH, Rinne UK, Tuominen J. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand 1989;126:113-118.
4. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
5. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245: 519-522.
6. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of parkinson's disease. Ann Neurol 1995;38:771-777.
7. Myllylä VV, Heinonen EH, Vuorinen JA, Kilkku OI, Sotaniemi KA. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease. Acta Neurol Scand 1995;91: 177-182.
8. Lees A, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-1607.
9. Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci 1992;19: 108-112.
10. Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO. Maintenance of L-deprenyl prolongs life in aged male rats. Life Sci 1990;47:415-420.
11. Knoll J, Dallo J, Yen TT. Striatal dopamine, sexual activity and lifespan: longevity of rats treated with (-)deprenyl. Life Sci 1989;45:525-531.
12. Kitani K, Kanai S, Sato Y, Ohta M, Ivy GO, Carrillo M-C. Chronic treatment with (-)deprenyl prolongs the life span of male Fischer 344 rats: further evidence. Life Sci 1993;52:281-288.
13. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar® treatment in Parkinson's disease: a long-term study. J Neural Transm 1985;64:113-127.
14. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality: a point of view. Ann Neurol 1996;40:841-845.
15. Olanow CV, Godbold JH, Koller W. Patients taking selegiline may have received more levodopa than necessary. BMJ 1996; 312:702-703.
16. Silva MT, Watts PM, Jenner P. Parkinson's disease is rarely a primary cause of death. BMJ 1996;312:703. Abstract.
17. Gerlach M, Riederer P, Vogt H. "On-treatment" rather than intention to treat analysis should have been used. BMJ 1996; 312:704. Abstract.
18. Jellinger KA. Causes of death need confirmation. BMJ 1996; 312:704. Abstract.
19. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenyl-pyridinium ion. J Neurochem 1985;45:1951-1953.
20. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-672.
21. + in vivo. Eur J Pharmacol 1993; 243:241-247.
22. Tatton WG, Ju WYL, Holland DP, Tai C, Kwan M. (-)-deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
23. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-Des-methylselegiline, a metabolite of L-(-)-selegiline, protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem 1997;68:434-436.
24. Mytilineou C, Leonardi EK, Radcliffe P, et al. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmacol Exp Ther 1998;284:700-706.
25. Myllylä VV, Sotaniemi KA, Hakulinen P, et al. Selegiline as the primary treatment of Parkinson's disease: a long-term double-blind study. Acta Neurol Scand 1997;95:211-228.
26. Pålhagen S, and the Swedish Parkinson Study Group. Selegiline delays the onset of disability in de novo patients with Parkinson's disease. Mov Disord 1996;11(suppl 1):552. Abstract.
27. Larsen JP, Boas J, and the Norwegian-Danish Study Group. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian-Danish 5-year study. Mov Disord 1997;12:175-182.
28. Przuntek H, Conrad B, Dichgans J, et al. Five-year analysis of the SELEDO study: proceedings of the 11th International Symposium on Parkinson's Disease, Rome. 1997:250. Abstract.
29. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomised clinical trials. Stat Med 1991;10:1665-1677.
30. Collet D. Modelling survival data in medical research. London: Chapman & Hall, 1994.
31. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to etiology. J Neurol Neurosurg Psychiatry 1995;58:293-299.
32. Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet 1991;338:1127-1130.
33. Moher D, Ingram O. Meta-analysis of randomized controlled trials: a concern of standards. JAMA 1995;274:1962-1963.
34. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309:1351-1355.
35. Rinne UK. Data on file, Orion Pharmaceuticals, Turku, Finland.
36. Caraceni T, Musicco M, and the Italian Parkinson Study Group. Direct dopamine agonists and MAO-B inhibitors in the prevention of L-dopa long-term syndrome: results of the Italian Multi-Center Trial. Proceedings of the XXII reunion of LIMPE, Viareggio, Italy, October 1996. Abstract.
37. Parkinson Study Group. Mortality in DATATOP: a multi-center trial in early Parkinson's disease. Ann Neurol 1998;43: 318-325.
38. Evans SJW, Sivananthan T. Does selegiline increase mortality? Proceedings of the fifth annual meeting of the European Society of Pharmacovigilance. Berlin, September 1997:44. Abstract.
39. DiRocco A, Culliton DA, Yahr MD. Comparative mortality and longevity in parkinsonian patients with L-dopa alone or L-dopa and selegiline. Mov Disord 1996;11(suppl 1):708. Abstract.
40. Fuell DL, Kreider M, Gardiner D. The effect of selegiline on the efficacy and safety of ropinirole in early and adjunct therapy studies in Parkinson's disease. Mov Disord 1997;12(suppl 1):437. Abstract.